Artelo Biosciences, Inc. (ARTL) News
Follow Artelo Biosciences, Inc. (ARTL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
Shares of GlucoTrack Inc (NASDAQ: GCTK ) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership. Innovate GBM, a non
LIVE | Sep 24, 2026, 09:05 AM UTC
L
ARTL - Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
ARTL - Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
NEWS | Sep 23, 2026, 11:33 AM UTC
L
ARTL - Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
ARTL - Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
NEWS | Sep 16, 2026, 11:30 AM UTC
L
Artelo Biosciences to Present at H.C. Wainwright Global Investment Conference
Artelo Biosciences said it will present at the H.C. Wainwright 28th Annual Global Investment Conference.
CRYPTO | Sep 08, 2026, 01:07 PM UTC
L
ARTL - Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
ARTL - Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 08, 2026, 01:02 PM UTC
L
Artelo Biosciences announces 1-for-9 reverse stock split
Artelo Biosciences announced a 1-for-9 reverse stock split.
EQUITY | Aug 27, 2026, 12:07 PM UTC
L
Artelo Biosciences reverse split being effected to lift share price
Artelo Biosciences says a reverse split is being effected to increase the price per share of common stock to improve marketability and liquidity.
EQUITY | Aug 27, 2026, 12:03 PM UTC
L
Artelo Biosciences gets Japan notice of allowance for ART27.13 formulation patents
Artelo Biosciences (ARTL) secures a notice of allowance in Japan covering patent claims for the intended commercial formulation of ART27.13.
REGULATION | Aug 20, 2026, 12:52 PM UTC
H
Artelo Biosciences receives USPTO notice of allowance for lead drug
Artelo Biosciences (ARTL) says it receives a Notice of Allowance from the U.S. Patent and Trademark Office for its lead investigational drug currently in two Phase 2 studies.
REGULATION | Aug 17, 2026, 12:53 PM UTC
L
Artelo Biosciences reports 2026 second-quarter results
Artelo Biosciences (ARTL) provides a business update and reports its 2026 second-quarter financial results, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 12:02 PM UTC
L
ARTL Artelo Biosciences announces results from a nonclinical osteoarthritis study supporting art26.12 as a potential first-in-class new ther
ARTL Artelo Biosciences announces results from a nonclinical osteoarthritis study supporting art26.12 as a potential first-in-class new therapy for chronic pain conditions
EQUITY | Jul 16, 2026, 12:48 PM UTC
L
Artelo Biosciences Announces Data From Preclinical Trial In Neuropathic Pain From Spinal Cord Injury Shows Lowered Mechanical Hypersensitivi
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derma
EQUITY | Jul 01, 2026, 12:43 PM UTC
L
Artelo Biosciences Identifies Lipid Pathway Link For ART26.12 In Multi-Omics Cancer Research Presentation At The CRS 2026 Annual Symposium
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological co
EQUITY | Jun 30, 2026, 12:59 PM UTC